Three out of every 100 children in the United States face the risk of permanent monocular vision loss due to amblyopia, a condition where the developing brain fails to process normal vision in one or both eyes. Because untreated amblyopia results in vision loss that cannot be corrected by glasses or contact lenses in adulthood, early intervention is critical. However, a significant geographic imbalance in the distribution of pediatric ophthalmologists and optometrists across the U.S. creates massive gaps in access to specialized care.
ANDI Automates Evidence-Based Clinical Pathways
To address this specialist shortage, the Pediatric Eye Disease Investigator Group (PEDIG) has launched the Amblyopia Navigator Decision-Support Instrument (ANDI). Developed by an NIH-funded research network of over 400 investigators, the tool distills findings from 147 published studies into actionable clinical advice. ANDI is designed to guide general eye care clinicians through the entire diagnostic and management lifecycle of pediatric amblyopia.
Once a diagnosis is made, the instrument assists clinicians without specialty training in determining optimal glasses prescriptions based on specific clinical findings. It also provides guidance on monitoring periods, noting that glasses alone can successfully improve vision in up to one-third of pediatric cases. If primary correction fails, ANDI walks the provider through secondary interventions, including patching the stronger eye, using atropine eye drops to induce temporary blurring, or implementing newer digital treatments delivered via specialized games and videos.
Managing Recurrence and Treatment Escalation
Effective management requires more than just initial treatment; it demands precise follow-up and the ability to recognize when a patient is stalling. ANDI provides specific logic for when a clinician should increase treatment intensity, switch therapeutic approaches, or reassess the underlying prescription. If progress ceases entirely, the tool advises when a formal referral to a pediatric specialist is necessary.
Beyond active treatment, the instrument provides structured steps for follow-up visits and identifies specific signs of recurrence that clinicians must monitor after a treatment course ends. By providing this level of granular, evidence-based guidance, ANDI enables general practitioners to provide high-level pediatric ophthalmic care in regions where specialists are entirely absent. This deployment of digital decision support aims to minimize the long-term impact of amblyopia on school performance, employment, and overall quality of life.
Source: NIH-supported project expands access to care for children with amblyopia
Domain: nih.gov
Comments load interactively on the live page.